M&A Deal Summary

Santen Pharmaceutical Acquires Eyevance Pharmaceuticals

On September 16, 2020, Santen Pharmaceutical acquired life science company Eyevance Pharmaceuticals from Avego Healthcare Capital

Acquisition Highlights
  • This is Santen Pharmaceutical’s 1st transaction in the Life Science sector.
  • This is Santen Pharmaceutical’s 2nd transaction in the United States.
  • This is Santen Pharmaceutical’s 1st transaction in Texas.

M&A Deal Summary
Date 2020-09-16
Target Eyevance Pharmaceuticals
Sector Life Science
Buyer(s) Santen Pharmaceutical
Sellers(s) Avego Healthcare Capital
Deal Type Add-on Acquisition

Target

Eyevance Pharmaceuticals

Fort Worth, Texas, United States
Eyevance Pharmaceuticals is committed to developing and commercializing innovative and impactful ophthalmic products that enable optimal vision, better quality of life, and address significant unmet medical needs. Eyevance Pharmaceuticals was founded in 2017 and is based in Fort Worth, Texas.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Santen Pharmaceutical

Osaka, Japan
Category Company
Founded 1890
Sector Life Science
Employees3,744
Revenue 302.0B JPY (2024)
DESCRIPTION

Santen Pharmaceutical is an entity which engages in the research, development, manufacture, and marketing of ophthalmic and anti-rheumatic pharmaceuticals for the protection and enhancement of eyesight and health. Santen Pharmaceutical was founded in 1890 and is based in Osaka, Japan.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 3 of 3
State (Texas) 1 of 1
Country (United States) 2 of 2
Year (2020) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-07-19 InnFocus

Miami, Florida, United States

InnFocus, Inc. is a developer of the InnFocus MicroShunt® (hereinafter, "MicroShunt") glaucoma implant device.

Buy $225M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-07-18 Santen - Branded Ophthalmic Portfolio

Osaka, Japan

Santen’s Branded Ophthalmic Portfolio Includes U.S. and Canadian commercial rights to Flarex, natacyn, tobradex st, verkazia, zerviate, and non-prescription brands freshkote and cationorm plus.

Sell -

Seller(S) 1

SELLER

Avego Healthcare Capital

Investor

Category Growth Capital Firm
Founded 2015
Size Small
Type Sector Focused
DESCRIPTION

Avego Healthcare Capital is a private investment firm focused on investing in expansion stage healthcare companies. Avego has a special interest in companies that are commercializing and developing important therapeutics, medical products, and services for patients, physicians, and other customers in the US and globally. Avego Healthcare Capital was formed in 2015 and is based in Alpharetta, Georgia.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Texas) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-04-16 Meridien Research

Winter Park, Florida, United States

Meridien Research is a multi-specialty clinical research site company which conducts Phase I-IV inpatient and outpatient clinical trials for global, mid-sized pharmaceutical and biotech sponsors, as well as the largest contract research organizations (“CROs”). Meridien’s research covers more than 50 indications, with the range of therapeutic areas spanning central nervous system, mental health, neurology, metabolic and endocrine disorders and women’s health. Meridien Research was founded in 2000 and is based in Winter Park, Florida.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-04-27 Arch Oncology

Brisbane, California, United States

Arch Oncology is a clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer. Arch Oncology is based in Brisbane, California.

Buy -
Mergr

Product

Company

Legal